Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases

肺生物学和肺部疾病中的干细胞、细胞疗法和生物工程

• 批准号: 10318408
• 负责人: Amy Leanne Ryan
• 金额: $ 3万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-23 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10318408
• 关键词: 3-Dimensional; Address; Adult Respiratory Distress Syndrome; American; Animal Model; Area; Award; Basic Science; Biology; Biomedical Engineering; Blinded; COVID-19; COVID-19 pandemic; Cell Therapy; Cells; Chest; Chronic Obstructive Airway Disease; Clinic; Clinical; Clinical Research; Clinical Trials; Communication; Communities; Critical Illness; Cystic Fibrosis; Data; Development; Disease; Equilibrium; European; Event; Faculty; Fostering; Foundations; Funding; Funding Agency; Funding Opportunities; Future; Goals; Grant; Growth; Guidelines; Hybrids; Immune response; Injury; International; Journals; Lung; Lung diseases; Malignant neoplasm of lung; Mentors; Minority; Minority Groups; Molecular; Motivation; National Heart, Lung, and Blood Institute; Natural regeneration; Oral; Participant; Pathologic; Persons; Pre-Clinical Model; Publishing; Pulmonary Fibrosis; Pulmonary Hypertension; Recommendation; Regulation; Research; Research Personnel; Research Support; Role; Science; Sepsis; Series; Societies; Stem Cell Research; Techniques; Technology; Therapeutic; Time; Tissue Engineering; Training; Translating; Translational Research; Transplantation; Travel; Underrepresented Minority; United States National Aeronautics and Space Administration; United States National Institutes of Health; Universities; Vermont; Woman; airway regeneration; base; career; career development; cell type; clinical investigation; combat; design; graduate student; induced pluripotent stem cell; innovation; insight; lung development; lung injury; lung regeneration; meetings; phrases; postdoctoral investigator; posters; repaired; respiratory; scaffold; skill acquisition; stem cell therapy; stem cells; symposium; translational study

Repair and regeneration of diseased lung with stem cells or bioengineered tissue are exciting potential therapeutic approaches for a variety of lung diseases and critical illnesses. Increasing evidence in preclinical models suggests that cells which are not normally resident in the lung can be utilized to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those utilizing stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise and differentiate during lung development and in normal and pathologic repair and remodeling after lung injury. We have held eight previous biennial conferences at the University of Vermont from 2005 through 2019. These have brought together leading international investigators with junior faculty and trainees to discuss issues in this rapidly moving field. These conferences have been highly successful and have resulted in a series of guidelines for basic, translational, and clinical research to be utilized by both investigators and funding agencies. As studies on stem cell and cell therapies for lung diseases continues to move at a rapid pace and the field explores how to best translate these approaches, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and leading non-profit respiratory disease foundations to discuss current issues. One area in particular to be discussed is the balance between basic and translational research and the role of clinical trials, particularly as there have now been clinical investigations of various cell types for a number of conditions including ARDS, BPD, COPD, IPF, pulmonary hypertension, sepsis, and more recently COVID-19. As with prior conferences a particular focus will be on rising junior investigators and trainees and how to further develop careers in this area. As always, junior investigators, trainees, and investigators from underrepresented minority groups will be prioritized for inclusion in conference organization, oral presentations, chairing activities, discussions, and poster sessions. Trainees will be able to compete for an increased number of travel awards based on blinded review of submitted abstracts. The conference is planned for July 2021 at the University of Vermont with plans for a switch from a hybrid conference to a fully online conference if necessary due to ongoing COVID-19 pandemic restrictions. We anticipate that this conference will continue to foster extensive discussion and debate and will significantly guide directions in basic, translational, and clinical research of stem cells, cell therapies, and bioengineering approaches for lung diseases.

用干细胞或生物工程组织的肺修复和再生具有令人兴奋的潜力 各种肺部疾病和重症疾病的治疗方法。临床前越来越多的证据 模型表明，通常不属于肺部的细胞可用于调节免疫 受伤后的反应，但在将这些有希望的发现转化为诊所方面存在挑战。在 平行于生物工程研究，调查了人造肺和细胞肺的使用 矩阵作为三维肺或气道再生的脚手架，最近尝试 大型动物模型中的移植。这些研究与利用干细胞的研究的结合， 诱导多能干细胞衍生物和/或细胞疗法是一项有希望且迅速发展的研究 区域。这些研究在理解分子和 内源性肺茎和/或祖细胞的细胞事件在肺中出现并分化 肺损伤后发育，正常和病理修复和重塑。我们持有八个 从2005年到2019年在佛蒙特大学举行的两年一次会议。这些带来了 领先的国际调查员与初级教师和学员一起讨论这个问题 移动场。这些会议非常成功，并为 研究人员和资助机构将使用基本，转化和临床研究。作为研究 关于肺部疾病的干细胞和细胞疗法，继续以快速的速度移动，该领域探讨了如何 为了最好地翻译这些方法，我们建议再次召集相关的研究人员以及 NHLBI，FDA和领先的非营利性呼吸道疾病基础的代表讨论当前 问题。特别要讨论的领域是基础研究和转化研究与 临床试验的作用，特别是因为现在已经对各种细胞类型进行了临床研究 包括ARDS，BPD，COPD，IPF，肺动脉高压，败血症等条件数量 新冠肺炎。与以前的会议一样 如何在这一领域进一步发展职业。与往常一样，初级调查员，学员和调查员 代表性不足的少数群体将优先考虑将会议组织，口头演示， 主持活动，讨论和海报会议。学员将能够争夺增加的人数 基于对提交摘要的盲目审查的旅行奖。该会议计划于2021年7月在 佛蒙特大学的计划从混合动力会议转换为完全在线会议的计划 由于持续的19日大流行限制，必要的。我们预计这次会议将继续 促进广泛的讨论和辩论，并将大力指导基本，转化和临床方面的方向 研究干细胞，细胞疗法和肺部疾病的生物工程方法。